AMCP Research Rundown — Spotlight on Precision Medicine
What has the AMCP Research Institute been working on lately? This week, we’re spotlighting research from ARI’s Precision Medicine Initiative that was recently presented at ISPOR Europe 2026 in Vienna, Austria! Our AMCP Principal Research Scientist Pam Pawloski, PharmD, BCOP, FCCP, presented the poster, Biomarker Testing in NSCLC: A Landscape Assessment of Administrative Data, which examined how biomarker testing has changed over time. Using a large U.S. multi-payer claims database, the study compared patients from 2010–2018 with those from 2019–2023.
The takeaway? We’re moving in the right direction. Biomarker testing increased over time across age, sex, and health plan coverage, and the use of targeted therapies increased among patients who received biomarker testing. At the same time, multi-gene panel testing remains low, reinforcing the need for continued progress in bringing precision medicine into everyday cancer care. This work helps identify where progress is being made and where opportunities remain to improve the use of biomarker testing to support more personalized treatment decisions.
A fun highlight from the conference: Pam’s poster earned a Top 5% ribbon out of 2,500 posters at ISPOR Europe! 🎉
As always, feel free to reach out to the AMCP Research Institute team with any questions about ARI’s work.
Julia Marsh
Director, Projects & Operations
Published on November 13, 2026
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.